Date Title Description PDF
26 Jun 2024 On corporate transactions ROVI notes the recent press speculation and informs about the assessment of potential strategic alternatives Download
24 Jun 2024 On business and financial situation ROVI publishes the press release in relation to information and guidance on its strategic plan for expansion and growth Download
08 May 2024 On P&L The Company releases the press release related to the first three months of 2024 financial results Download
08 May 2024 On P&L The Company releases the first three months 2024 financial results presentation Download
25 Apr 2024 On business and financial situation ROVI announces agreement to manufacture pre-filled syringes Download

Pages

Date Title Description PDF
02 Jul 2021 Other relevant information The Company informs about the dividends payment  Download
17 Jun 2021 Announcement of general shareholders’ meeting ROVI releases the information related to its General Shareholders Meeting Download
13 May 2021 On business and financial situation The company releases the press release related to first quarter 2021 financial results Download
13 May 2021 On business and financial situation ROVI releases the first quarter 2021 results presentation Download
13 May 2021 Announcement of general shareholders’ meeting Rovi releases the information related to its 2021 General Shareholders Meeting Download

Pages

Date Title Description PDF
08 Jan 2018 Contratos de liquidez y contrapartida Liquidity contract: transactions conducted in the fourth quarter of 2017 Download
21 Dec 2017 Préstamos, créditos y avales ROVI and the EIB agree to sign a loan to boost research into drug administration and prolonged-release technologies Download
08 Nov 2017 Información sobre Resultados ROVI releases the press release related to the nine-month period ended 30 September 2017 results Download
08 Nov 2017 Información sobre Resultados ROVI releases the presentation related to the nine-month period ended 30 September 2017 results. Download
24 Oct 2017 Otros sobre negocio y situación financiera The Company releases the presentation related to the update of its Phase III-Prima 3 Risperidone ISM® project. Download

Pages